Page 81 - 2019_04-Haematologica-web

AZA or LEN plus AZA in MDS, CMML and low blast AML
difficult to ensure. A more robust, refined IWG criteria is awaited and would make this more consistent in future studies.
We have shown the feasibility on a broad scale of the combination of lenalidomide and azacitidine in patients with higher risk MDS, CMML and low blast count AML, but the lack of improvement in responses and clinical benefit do not support the utilization of this combination in higher-risk MDS in clinical practice. Other combina- tions and novel agents are needed to improve the out- comes for this large and vulnerable group of patients, who at this stage have limited therapeutic options. Other
groups are currently exploring novel combination studies with azacitidine such as enasidinib and venetoclax.
Acknowledgments
The authors wish to acknowledge the Australasian Leukaemia & Lymphoma Group for conduct of the study, all site investigators and study personnel. We also wish to thank our patients and families.
Funding
This study was supported by Celgene with grant funding for study conduct, Snowdome Foundation and the Victorian Epigenetic Group for funding support for molecular studies.
References
1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization Classification of Myeloid neoplasms and Acute leukemia. Blood. 2016;127(20):2391-2405.
2. Gangat N, Patnaik MM, & Tefferi A. Myelodysplastic syndromes: Contemporary Review and how we treat. Am J Hematol. 2016;91(1):76-89.
3. Shukron O, Vainstein V, Kündgen A, Germing U, & Agur Z. Analyzing transfor- mation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database. Am J Hematol. 2012;87(9):853-860.
4. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
blast count acute myeloid leukemia. J Clin
Oncol. 2010;28(4):562-569.
12. Ball B, Zeidan A, Gore SD & Prebet T.
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leuk Lymphoma. 2017;58(5):1022-1036.
13. Rami SK, Sallman D, Ali M, et al. Outcome of myelodysplastic syndrome patients with TP53 mutation treated with hypomethylat- ing agents. Blood. 2017;130(Suppl 1):1687.
14. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36
15. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syn- dromes. N Engl J Med. 2005;352(6):549- 557.
16. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalido- mide versus placebo in RBC transfusion- dependent patients with low-/intermedi- ate-1-risk myelodysplastic syndromes with del5q. Blood. 2011; 118(14):3765-3776.
17. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion- dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with kary- otypes other than deletion 5q. Blood 2008;111(1):86-93.
myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017;35(24):2745-2753.
22. Narayan R, Garcia JS, Percival MM, et al. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leuk Lymphoma. 2016;57(3):609-615.
23. DiNardo CD, Daver N, Jabbour, et al. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia: a single arm, phase 1/2 study. Lancet Haematol. 2015;2(1):e12-e20.
24. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th Edition. International Agency for Research on Cancer (2008).
25. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27(11):1850-1856.
26. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010;28(13):2253-2258.
27. Cheson BD, Greenberg PL, Bennett J, et al. Clinical application and proposal for modi- fication of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-
5. Greenberg P, Cox C, LeBeau, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
6. Christman JK. 5-Azacytidine and 5-aza-2′- deoxycytidine as inhibitors of DNA methy- lation: mechanistic studies and their impli- cations for cancer therapy. Oncogene. 2012;21(35):5483-5495.
7. Silverman LR, Demakos E. Peterson B, et al. Randomized controlled trial of azaciti- dine in patients with the myelodysplastic yndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20(10):2429-2440.
8. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syn- drome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol. 2002;20(10):2441-2452.
9. Fenaux P, Mufti GJ, Hellstrom E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treat- ment of higher-risk myelodysplastic syn- dromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
10. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of Azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. Blood. 2015;126(3):291-299.
11. Fenaux P, Mufti,GJ, Hellstrom E, et al. Azacitidine prolongs overall survival com- pared with conventional care regimens in elderly patients with low bone marrow
18. Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalido-
mide versus placebo in RBC transfusion-
dependent patients with lower-risk non-
del(5q) myelodysplastic syndromes and
ineligible for or refractory to erythro- 425.
poiesis-stimulating agents. J Clin Oncol.
2016;34(25):2988-2996.
19. Sibon D, Cannas G, Baracco F. et al.
Lenalidomide in lower-risk myelodysplas- tic syndromes with karyotypes other than deletion 5q and refractory to erythro- poiesis-stimulating agents. Br J Haematol. 2012;156(5):619-625.
20. Kenealy M, Patton N, Filshie R, et al. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leuk Lymphoma. 2017;58(2):298-307.
21. Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodys- plastic syndromes and chronic
28. Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 2014;99(6):956-964.
29. Kulasekararaj AG, Mohamedali AM, & Mufti GJ. Recent advances in understand- ing the molecular pathogenesis of myelodysplastic syndromes. Br J Haematol. 2013;162(5):587-605.
30. Medeiros BC, McCaul K, Kambhampati S, et al. Randomized study of continuous high dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly diagnosed acute myeloid leukemia. Haematologica. 2018;103(1):101-106.
31. Zeidan AM, Al Ali NH, Padron E, et al. Lenalidomide treatment for lower risk non- deletion 5q myelodysplastic syndromes patients yields higher response rates when used before Azacitidine. Clin Lymphoma Myeloma Leuk. 2015;15(11):705-710.
haematologica | 2019; 104(4)
709